{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:50:52Z","timestamp":1782604252170,"version":"3.54.5"},"reference-count":216,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.jaad.2006.04.048","type":"journal-article","created":{"date-parts":[[2007,1,14]],"date-time":"2007-01-14T07:07:09Z","timestamp":1168758429000},"page":"181-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":241,"title":["Toxic epidermal necrolysis"],"prefix":"10.1016","volume":"56","author":[{"given":"Frederick A.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh Vijay","family":"Mudgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.04.048_bib1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archderm.1987.01660330067010","article-title":"Treatment of toxic epidermal necrolysis. Creteil's experience","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0738-081X(93)90156-7","article-title":"Drug-induced toxic epidermal necrolysis. II. Current aspects","volume":"11","author":"Roujeau","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0738-081X(98)00011-X","article-title":"Drug-induced toxic epidermal necrolysis","volume":"16","author":"Wolkenstein","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1346-8138.1998.tb02450.x","article-title":"Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium","volume":"25","author":"Sugimoto","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archderm.141.6.775","article-title":"Cell-mediated immunologic mechanism and severity of TEN","volume":"141","author":"Faye","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70196-0","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Wolkenstein","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2006.04.048_bib9","first-page":"5","article-title":"Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"},{"issue":"12 Pt 2","key":"10.1016\/j.jaad.2006.04.048_bib10","first-page":"1522","article-title":"Intense pulsed light treatment of persistent facial hypermelanosis following drug-induced toxic epidermal necrolysis","volume":"30","author":"Paquet","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2006.04.048_bib11","first-page":"153","article-title":"Vulvovaginal sequelae in toxic epidermal necrolysis","volume":"42","author":"Meneux","year":"1997","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jaad.2006.04.048_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.109.1.74","article-title":"Long-term consequences of toxic epidermal necrolysis in children","volume":"109","author":"Sheridan","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2006.04.048_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2230.1990.tb02112.x","article-title":"Introital adenosis associated with the Stevens-Johnson syndrome","volume":"15","author":"Bonafe","year":"1990","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2133.2005.06751.x","article-title":"Vulval adenosis associated with toxic epidermal necrolysis","volume":"153","author":"Noel","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib16","first-page":"143","article-title":"Introital adenosis associated with Stevens-Johnson syndrome","volume":"66","author":"Marquette","year":"1985","journal-title":"Obstet Gynecol"},{"issue":"3 Pt 2","key":"10.1016\/j.jaad.2006.04.048_bib17","first-page":"478","article-title":"Vulvovaginal sequelae of Stevens-Johnson syndrome and their management","volume":"71","author":"Wilson","year":"1988","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jaad.2006.04.048_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2004.11.035","article-title":"Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome","volume":"112","author":"Di Pascuale","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2006.04.048_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archpedi.1922.04120120077005","article-title":"A new eruptive fever associated with stomatitis and ophthalmia","volume":"24","author":"Stevens","year":"1922","journal-title":"American Journal of Diseases of Children"},{"key":"10.1016\/j.jaad.2006.04.048_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(85)92146-4","article-title":"Sj\u00f6gren-like syndrome after drug-induced toxic epidermal necrolysis","volume":"1","author":"Roujeau","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous-membrane involvement and Stevens-Johnson Syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of\u00a0an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1523-1747.1999.00754.x","article-title":"Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions","volume":"113","author":"Kokuba","year":"1999","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2133.2004.06258.x","article-title":"Toxic epidermal necrolysis in a premature infant of 27 weeks' gestational age","volume":"152","author":"Lohmeier","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ageing\/22.6.450","article-title":"Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients","volume":"22","author":"Bastuji-Garin","year":"1993","journal-title":"Age Ageing"},{"key":"10.1016\/j.jaad.2006.04.048_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2006.04.048_bib29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/pds.1105","article-title":"Cutaneous adverse drug reactions: a 9-year study from a South Indian Hospital","volume":"14","author":"Sushma","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2006.04.048_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archderm.1984.01650420031010","article-title":"Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator","volume":"120","author":"Westly","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00004630-199711000-00009","article-title":"Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage","volume":"18","author":"Engelhardt","year":"1997","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib34","first-page":"59","article-title":"Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination","volume":"13","author":"Dobrosavljevic","year":"1999","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2006.04.048_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.1974.01630070067017","article-title":"Fumigant-induced toxic epidermal necrolysis","volume":"110","author":"Radimer","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2006.04.048_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00043764-199202000-00012","article-title":"Work-related toxic epidermal necrolysis?","volume":"34","author":"House","year":"1992","journal-title":"J Occup Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib38","first-page":"366","article-title":"Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children","volume":"37","author":"Lam","year":"2004","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jaad.2006.04.048_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/adc.53.1.38","article-title":"Mycoplasma pneumoniae infections in children","volume":"53","author":"Stevens","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2006.04.048_bib40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jaad.2006.04.048_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0161-6420(01)00900-9","article-title":"Amniotic membrane in the surgical management of acute toxic epidermal necrolysis","volume":"109","author":"John","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2006.04.048_bib42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The\u00a0culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib43","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib44","first-page":"1325","article-title":"[Antiretroviral-induced toxiderma in HIV-infected patients]","volume":"32","author":"Caumes","year":"2003","journal-title":"Presse Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2006.04.048_bib46","series-title":"Litt's Drug Eruption Reference Manual","author":"Litt","year":"2004"},{"key":"10.1016\/j.jaad.2006.04.048_bib47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1445-5994.2005.00790.x","article-title":"Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"35","author":"Lin","year":"2005","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaad.2006.04.048_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/502233","article-title":"Toxic epidermal necrolysis after topical intranasal application of mupirocin","volume":"24","author":"Praz","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jaad.2006.04.048_bib49","first-page":"3631","article-title":"[Toxic epidermal necrolysis following intake of vitamins and natural medication]","volume":"157","author":"Fogh","year":"1995","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.jaad.2006.04.048_bib50","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1346-8138.1998.tb02477.x","article-title":"Stevens-Johnson syndrome caused by a health drink (Eberu) containing ophiopogonis tuber","volume":"25","author":"Mochitomi","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib51","first-page":"714","article-title":"Serious cutaneous adverse reactions to traditional Chinese medicines","volume":"46","author":"Lim","year":"2005","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jaad.2006.04.048_bib52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archderm.141.7.907","article-title":"Pseudoephedrine-induced toxic epidermal necrolysis","volume":"141","author":"Nagge","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1046\/j.1365-2133.1996.d01-1111.x","article-title":"Photo-induced toxic epidermal necrolysis caused by clobazam","volume":"135","author":"Redondo","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0781.2005.00149.x","article-title":"A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin","volume":"21","author":"Mansur","year":"2005","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2006.04.048_bib55","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1097\/00003246-200211000-00029","article-title":"Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability","volume":"30","author":"Paquet","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.iac.2004.03.011","article-title":"Sulfonamide hypersensitivity","volume":"24","author":"Slatore","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaad.2006.04.048_bib57","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib58","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2006.04.048_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1592\/phco.19.3.223.30917","article-title":"Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies","volume":"19","author":"Micali","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2006.04.048_bib60","first-page":"1056","article-title":"[Stevens-Johnson syndrome, toxic epidermal necrolysis and phenytoin. Factors linked to a higher risk]","volume":"38","author":"Gomez-Criado","year":"2004","journal-title":"Rev\u00a0Neurol"},{"key":"10.1016\/j.jaad.2006.04.048_bib61","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/B:NEON.0000014538.31561.bc","article-title":"Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider","volume":"66","author":"Aguiar","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jaad.2006.04.048_bib62","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)11369-1","article-title":"Toxic epidermal necrolysis","volume":"351","author":"Becker","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib63","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archderm.141.6.683","article-title":"Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis","volume":"141","author":"Quinn","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib64","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1975.01630230035004","article-title":"Toxic epidermal necrolysis. Rapid differentiation between staphylococcal- and drug-induced disease","volume":"111","author":"Amon","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bjps.2004.04.025","article-title":"Lyell syndrome revisited: analysis of 18 cases of severe bullous skin disease in a burns unit","volume":"58","author":"Neff","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.jaad.2006.04.048_bib66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.0022-202X.2005.23642.x","article-title":"Epidemiology of staphylococcal scalded skin syndrome in Germany","volume":"124","author":"Mockenhaupt","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib67","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1128\/JCM.43.4.1890-1893.2005","article-title":"Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins","volume":"43","author":"Yamasaki","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jaad.2006.04.048_bib68","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1198-743x.2001.00258.x","article-title":"Recent developments in staphylococcal scalded skin syndrome","volume":"7","author":"Ladhani","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaad.2006.04.048_bib69","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1128\/JCM.39.6.2050-2054.2001","article-title":"Development and evaluation of detection systems for staphylococcal exfoliative toxin A responsible for scalded-skin syndrome","volume":"39","author":"Ladhani","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jaad.2006.04.048_bib70","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1346-8138.1990.tb01689.x","article-title":"Action of staphylococcal exfoliative toxins on epidermal cell cultures and organotypic skin","volume":"17","author":"Gentilhomme","year":"1990","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib71","first-page":"165","article-title":"Depot sulfonamid associated linear IgA bullous dermatosis with erythema multiforme-like clinical features","volume":"11","author":"Tonev","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2006.04.048_bib72","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0738-081X(93)90161-5","article-title":"Drug-induced linear immunoglobulin A disease","volume":"11","author":"Collier","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib73","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1592\/phco.25.2.308.56953","article-title":"Probable vancomycin-associated toxic epidermal necrolysis","volume":"25","author":"Craycraft","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2006.04.048_bib74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0738-081X(98)00009-1","article-title":"Drug-induced linear immunoglobulin-A bullous dermatosis","volume":"16","author":"Camilleri","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib75","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","article-title":"Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia","volume":"323","author":"Anhalt","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2005.126_1.x","article-title":"Paraneoplastic pemphigus: a brief update","volume":"46","author":"Wade","year":"2005","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2133.2001.04296.x","article-title":"Paraneoplastic pemphigus. A report of two cases associated with chronic B-cell lymphocytic leukaemia","volume":"145","author":"Marzano","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib78","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clindermatol.2004.06.005","article-title":"Life-threatening graft-vs-host disease","volume":"23","author":"Vargas-Diez","year":"2005","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib80","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archderm.1988.01670050032014","article-title":"Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation","volume":"124","author":"Friedman","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib81","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0738-081X(98)00010-8","article-title":"Drug-induced pemphigus","volume":"16","author":"Brenner","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib82","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0738-081X(93)90158-9","article-title":"Drug-induced pemphigus. II. Pathomechanisms and experimental investigations","volume":"11","author":"Ruocco","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib83","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0733-8635(18)30243-2","article-title":"Drug-induced pemphigus","volume":"11","author":"Mutasim","year":"1993","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2006.04.048_bib84","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","article-title":"Drugs associated with bullous pemphigoid. A case-control study","volume":"132","author":"Bastuji-Garin","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib85","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0738-081X(93)90159-A","article-title":"Drug-induced bullous pemphigoid","volume":"11","author":"Fellner","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib86","first-page":"37","article-title":"[Acute generalized exanthematic pustuloses (four cases) (author's transl)]","volume":"107","author":"Beylot","year":"1980","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2006.04.048_bib87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-4362.2001.01241.x","article-title":"Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis","volume":"40","author":"Cohen","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib88","first-page":"475","article-title":"Acute generalized exanthematous pustulosis with erythema multiforme-like lesions","volume":"12","author":"Lin","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib89","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib90","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2006.04.048_bib91","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"key":"10.1016\/j.jaad.2006.04.048_bib92","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B\u22175701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib93","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib94","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0140-6736(02)07899-6","article-title":"Individualising HIV treatment\u2014pharmacogenetics and immunogenetics","volume":"359","author":"Telenti","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib95","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0733-8635(05)70309-0","article-title":"New advances in severe adverse drug reactions","volume":"19","author":"Revuz","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2006.04.048_bib96","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9120(00)00146-6","article-title":"A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes","volume":"33","author":"Neuman","year":"2000","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaad.2006.04.048_bib97","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMcp043986","article-title":"Clinical practice. Antibiotic allergy","volume":"354","author":"Gruchalla","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib99","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib100","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archderm.1994.01690050066011","article-title":"Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine","volume":"130","author":"Friedmann","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib101","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archderm.138.1.29","article-title":"Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples","volume":"138","author":"Correia","year":"2002","journal-title":"Arch Dermatol"},{"issue":"1 Pt 1","key":"10.1016\/j.jaad.2006.04.048_bib102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0091-6749(00)90191-X","article-title":"Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response","volume":"105","author":"Leyva","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib104","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2006.04.048_bib106","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.1990.tb08240.x","article-title":"Monoclonal antibody MAC 387 recognizes a myelomonocytic antigen shared by epithelial cells in inflammatory skin diseases","volume":"122","author":"Kirkham","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib107","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2133.2000.03595.x","article-title":"Cytological alterations in dermal dendrocytes in vitro: evidence for transformation to a non-dendritic phenotype","volume":"143","author":"Monteiro","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib108","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000069961","article-title":"Factor-XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes","volume":"206","author":"Paquet","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.04.048_bib109","series-title":"Immunobiology: the immune system in health and disease","author":"Janeway","year":"2001"},{"key":"10.1016\/j.jaad.2006.04.048_bib110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib111","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaad.2006.04.048_bib112","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","article-title":"Death receptors in cutaneous biology and disease","volume":"115","author":"Wehrli","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.cdd.4401185","article-title":"Protein-based therapeutic approaches targeting death receptors","volume":"10","author":"French","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jaad.2006.04.048_bib114","doi-asserted-by":"crossref","first-page":"16183","DOI":"10.1074\/jbc.M212188200","article-title":"Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2006.04.048_bib115","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/cncr.10277","article-title":"Expression of CD95 (Fas) in sun-exposed human skin and cutaneous carcinomas","volume":"94","author":"Filipowicz","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2006.04.048_bib116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nm0198-031","article-title":"Downregulation of Fas ligand by shedding","volume":"4","author":"Tanaka","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib117","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.170.2.677","article-title":"Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand","volume":"170","author":"Knox","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib118","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archderm.140.2.242","article-title":"Kinetics and specificity of fas ligand induction in toxic epidermal necrolysis","volume":"140","author":"Chang","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib119","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2006.04.048_bib120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib121","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib122","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib124","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00403-004-0506-z","article-title":"Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome","volume":"296","author":"Gaultier","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2006.04.048_bib125","first-page":"145","article-title":"Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin","volume":"10","author":"Paquet","year":"2002","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib126","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-1747.2000.00816.x","article-title":"Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"114","author":"Lerner","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib127","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2222.2003.01718.x","article-title":"Mechanisms in cutaneous drug hypersensitivity reactions","volume":"33","author":"Friedmann","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaad.2006.04.048_bib128","series-title":"Goodman and Gilman's: The Pharmacological basis of therapeutics","author":"Hardman","year":"1996"},{"key":"10.1016\/j.jaad.2006.04.048_bib129","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib130","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(00)03137-8","article-title":"Idiosyncratic drug reactions: the reactive metabolite syndromes","volume":"356","author":"Knowles","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1385\/CRIAI:24:3:229","article-title":"Reactive metabolites and\u00a0adverse drug reactions: clinical considerations","volume":"24","author":"Knowles","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib132","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bmj.312.7024.173","article-title":"Allopurinol, erythema multiforme, and renal insufficiency","volume":"312","author":"Kumar","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2006.04.048_bib133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib134","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.iac.2004.03.006","article-title":"HIV and drug allergy","volume":"24","author":"Temesgen","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaad.2006.04.048_bib135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2230.1997.tb01038.x","article-title":"Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR)","volume":"22","author":"Smith","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib136","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1345\/aph.18383","article-title":"Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome","volume":"33","author":"Mylonakis","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2006.04.048_bib137","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/j.1875-9114.1998.tb03868.x","article-title":"Fatal toxic epidermal necrolysis related to lamotrigine administration","volume":"18","author":"Page","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2006.04.048_bib138","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000245690","article-title":"Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro","volume":"195","author":"Sachs","year":"1997","journal-title":"Dermatology"},{"issue":"5 Pt 2","key":"10.1016\/j.jaad.2006.04.048_bib139","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1067\/mjd.2000.100544","article-title":"Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid","volume":"43","author":"Yalcin","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib140","first-page":"46","article-title":"[Lyell syndrome and Stevens-Johnson syndrome caused by lamotrigine]","volume":"126","author":"Bocquet","year":"1999","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2006.04.048_bib141","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S0004-282X1996000100008","article-title":"Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk","volume":"54","author":"Li","year":"1996","journal-title":"Arq Neuropsiquiatr"},{"issue":"Suppl 7","key":"10.1016\/j.jaad.2006.04.048_bib142","first-page":"S22","article-title":"Lamotrigine-induced severe cutaneous adverse reactions","volume":"39","author":"Schlienger","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaad.2006.04.048_bib143","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.phrs.2003.05.003","article-title":"Adverse drug reactions: role of pharmacogenomics","volume":"49","author":"Severino","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jaad.2006.04.048_bib144","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0625.1995.tb00211.x","article-title":"Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Dietrich","year":"1995","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00403-003-0446-z","article-title":"Glutathione S-transferase polymorphisms in patients with drug eruption","volume":"295","author":"Ates","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2006.04.048_bib146","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.56.7.890","article-title":"TNF-alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients","volume":"56","author":"Pirmohamed","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2006.04.048_bib147","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tox.2003.12.008","article-title":"A chemically inert drug can stimulate T cells in vitro by their T\u00a0cell receptor in non-sensitised individuals","volume":"197","author":"Engler","year":"2004","journal-title":"Toxicology"},{"key":"10.1016\/j.jaad.2006.04.048_bib148","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib149","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0300-483X(02)00254-8","article-title":"Modes of presentation of chemical neoantigens to the immune system","volume":"181-182","author":"Pichler","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.jaad.2006.04.048_bib150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib151","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib152","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004630-199601000-00008","article-title":"Experience with toxic epidermal necrolysis treated in a burn center","volume":"17","author":"Yarbrough","year":"1996","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib153","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burns centre: a 6-year review","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2006.04.048_bib154","first-page":"347","article-title":"Treatment of toxic epidermal necrolysis in a burn center","volume":"93","author":"Yarbrough","year":"1997","journal-title":"J S C Med Assoc"},{"key":"10.1016\/j.jaad.2006.04.048_bib155","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2006.04.048_bib156","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib157","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/milmed\/167.8.701","article-title":"A case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis to a burn center","volume":"167","author":"Ellis","year":"2002","journal-title":"Mil Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib158","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A\u00a010-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib159","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ophtha.2005.09.001","article-title":"Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2006.04.048_bib160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/00005373-198610000-00016","article-title":"Use of amnion for the treatment of Stevens-Johnson syndrome","volume":"26","author":"Prasad","year":"1986","journal-title":"J Trauma"},{"key":"10.1016\/j.jaad.2006.04.048_bib161","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1542\/peds.108.5.1162","article-title":"Treatment of extensive toxic epidermal necrolysis in children","volume":"108","author":"Spies","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2006.04.048_bib162","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00004630-199920060-00012","article-title":"Management of severe toxic epidermal necrolysis in children","volume":"20","author":"Sheridan","year":"1999","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib163","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.jaad.2006.04.048_bib164","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.jaad.2006.04.048_bib166","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","article-title":"A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis","volume":"2","author":"Yamada","year":"1998","journal-title":"Ther Apher"},{"key":"10.1016\/j.jaad.2006.04.048_bib167","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke","year":"1999","journal-title":"Intensive\u00a0Care Med"},{"key":"10.1016\/j.jaad.2006.04.048_bib168","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangogiannis","year":"1996","journal-title":"South Med J"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2006.04.048_bib169","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib170","first-page":"473","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J\u00a0Trauma"},{"key":"10.1016\/j.jaad.2006.04.048_bib171","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000018112","article-title":"Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?","volume":"198","author":"Paquet","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.04.048_bib172","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-4362.1989.tb02502.x","article-title":"Drug-induced toxic epidermal necrolysis treated with cyclosporin","volume":"28","author":"Renfro","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib173","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2230.1992.tb02163.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin","volume":"17","author":"Hewitt","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib174","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib175","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1365-4362.1997.00100.x","article-title":"Toxic epidermal necrolysis\u2014a retrospective study","volume":"36","author":"Criton","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib176","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaad.2006.04.048_bib177","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archderm.1995.01690180043007","article-title":"Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy","volume":"131","author":"Guibal","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib178","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1525-1470.2002.00002.x","article-title":"Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy","volume":"19","author":"Samimi","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib179","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2230.2001.00910.x","article-title":"Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam","volume":"26","author":"van der Meer","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2006.04.048_bib180","article-title":"Toxic epidermal necrolysis\/Stevens Johnson syndrome: Positive outcome after treatment with dexamethasone pulse therapy","volume":"123","author":"Kardaun","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2006.04.048_bib181","article-title":"Evaluation of treatment efficacy in a cohort of 281 patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)","volume":"123","author":"Schlingman","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib182","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.04.048_bib183","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.19.15.1177.30571","article-title":"Thalidomide-induced toxic epidermal necrolysis","volume":"19","author":"Horowitz","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2006.04.048_bib184","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib185","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1346-8138.1999.tb02082.x","article-title":"Treatment of severe drug eruptions","volume":"26","author":"Roujeau","year":"1999","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib186","series-title":"Intravenous immunoglobulin in dermatology","author":"Jolles","year":"2003"},{"key":"10.1016\/j.jaad.2006.04.048_bib187","first-page":"1656","article-title":"Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition","volume":"130","author":"French","year":"2000","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.jaad.2006.04.048_bib188","first-page":"266","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin","volume":"155","author":"Simeone","year":"2003","journal-title":"J La State Med Soc"},{"key":"10.1016\/j.jaad.2006.04.048_bib189","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1081-1206(10)62065-0","article-title":"Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin","volume":"91","author":"Mayorga","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib190","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1742-1241.2003.tb10578.x","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin","volume":"57","author":"Sidwell","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaad.2006.04.048_bib191","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2230.2003.01255.x","article-title":"Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins","volume":"28","author":"Tan","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib192","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib193","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1440-0960.1999.00347.x","article-title":"Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin","volume":"40","author":"Phan","year":"1999","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib194","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0305-4179(01)00005-5","article-title":"Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins","volume":"27","author":"Paquet","year":"2001","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2006.04.048_bib195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib196","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib197","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib198","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib199","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"issue":"6 Pt 1","key":"10.1016\/j.jaad.2006.04.048_bib200","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2006.04.048_bib201","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in\u00a0Stevens-Johnson syndrome: a retrospective, multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.04.048_bib202","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2003.07.017","article-title":"Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome","volume":"50","author":"Hebert","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib203","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1748-5827.2004.tb00248.x","article-title":"Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog","volume":"45","author":"Nuttall","year":"2004","journal-title":"J Small Anim Pract"},{"key":"10.1016\/j.jaad.2006.04.048_bib204","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib205","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2006.04.048_bib206","first-page":"2494","article-title":"Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome","volume":"27","author":"Morici","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib207","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.eye.6701653","article-title":"High-dose intravenous immunoglobulin in the treatment of\u00a0toxic epidermal necrolysis: a study of ocular benefits","volume":"19","author":"Yip","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.jaad.2006.04.048_bib208","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archderm.139.1.85","article-title":"Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing","volume":"139","author":"Wolff","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib209","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00128071-200405030-00003","article-title":"Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view","volume":"5","author":"Ruetter","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib210","series-title":"Intravenous immunoglobulin in dermatology","first-page":"79","article-title":"Toxic epidermal necrolysis","author":"Craven","year":"2003"},{"key":"10.1016\/j.jaad.2006.04.048_bib211","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2006.04.048_bib212","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2230.2005.01863.x","article-title":"The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"30","author":"Yeung","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib213","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/00007611-199909000-00015","article-title":"Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor","volume":"92","author":"Winfred","year":"1999","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2006.04.048_bib214","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2133.1996.tb01167.x","article-title":"Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis","volume":"135","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.04.048_bib215","first-page":"392","article-title":"Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor","volume":"41","author":"Kalyoncu","year":"2004","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.jaad.2006.04.048_bib216","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/apc.1997.11.125","article-title":"Management of a patient with advanced AIDS and toxic epidermal necrolysis using human growth hormone and G-CSF","volume":"11","author":"Bae","year":"1997","journal-title":"AIDS Patient Care STDS"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206012230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206012230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:05:03Z","timestamp":1759269903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206012230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":216,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0190962206012230"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.04.048","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}